Table 3:
Significantly Differentially Expressed Proteins in Plasma and Cerebrospinal Fluid from Baseline to Post-Treatment
| Protein (pg/mL) | Baseline Mean (SD) | Post-Treatment Mean (SD) | Fold Change | T-test(df), p-value |
|---|---|---|---|---|
| Plasma | ||||
| *IL6 | 1.30 (0.54) | 1.58 (0.81) | 1.22 | t(4)= 1.651, p=0.145 |
| IL-17E | 25.2 (20.3) | 17.0 (14.5) | 0.67 | t(4)= −5.216, p=0.0014 |
| IL-21 | 166 (96.7) | 102 (72.1) | 0.62 | t(4)=−4.714, p=0.002 |
| IL-23 | 53.4 (29.5) | 34.0 (25.4) | 0.64 | t(4)=−4.345, p=0.003 |
| IL-17A/F | 35.4 (12.8) | 23.1 (12.7) | 0.65 | t(4)=−3.870, p=0.007 |
| IL-17D | 67.7 (25.5) | 49.0 (17.9) | 0.72 | t(4)=−3.384, p=0.013 |
| IL-10 | 0.31 (1.0) | 0.21 (0.20) | 0.66 | t(4)=−3.347, p=0.013 |
| VEGF | 20.8 (6.0) | 12.5 (3.4) | 0.60 | t(4)=−3.238, p=0.015 |
| YKL-40 | 58047 (60143) | 105444 (127256) | 1.82 | t(4)=3.017, p=0.020 |
| IL-31 | 67.5 (27.9) | 54.8 (28.9) | 0.81 | t(4)=−2.914, p=0.024 |
| MCP-2 | 23.5 (5.1) | 18.5 (4.5) | 0.79 | t(4)=−2.806, p=0.028 |
| MIP-1β | 48.5 (16.1) | 36.9 (25.8) | 0.76 | t(4)=−2.515, p=0.042 |
| MIP-1α | 24.3 (1.6) | 19.6 (4.7) | 0.81 | t(4)=−2.433, p=0.047 |
| Cerebrospinal Fluid | ||||
| *IL-6 | 1.16 (0.32) | 1.55 (0.23) | 1.34 | t(4)=3.913, p=0.008 |
| TARC | 1.42 (0.42) | 1.25 (0.38) | 0.87 | t(4)=−3.099, p=0.021 |
| IL-17A | 0.54 (0.13) | 0.35 (0.11) | 0.60 | t(4)=−2.753, p=0.033 |
| I-TAC | 4.15 (1.2) | 3.36 (1.1) | 0.81 | t(4)=−2.736, p=0.033 |
| Eotaxin-2 | 14.5 (6.5) | 12.8 (5.3) | 0.89 | t(4)=−2.630, p=0.038 |
| Eotaxin | 16.9 (4.9) | 14.7 (4.3) | 0.87 | t(4)=−2.534, p=0.044 |
| MIP-1α | 19.0 (2.4) | 14.3 (4.8) | 0.75 | t(4)=−2.471, p= 0.048 |
Note: Differential expression analysis was carried out by the moderated t-test
*:
Prespecified secondary outcome
IL = interleukin, MIP = Macrophage Inflammatory Protein, G-CSF = Granulocyte Colony-Stimulating Factor, TRAIL = Tumor Necrosis Factor Related Apoptosis-Inducing Ligand, TARC = Thymus- and Activation-Regulated Chemokine, p<0.05